LP-184 is under clinical development by Lantern Pharma and currently in Phase I for Lung Cancer. According to GlobalData, Phase I drugs for Lung Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LP-184’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LP-184 overview

LP-184 is under development for the treatment of ovarian cancer, prostate cancer, colorectal cancers, pancreatic cancer, liver cancer, neurological cancers, glioblastoma multiforme, malignant glioma, recurrent glioblastoma multiforme, high-grade glioma, bladder cancer, atypical teratoid rhabdoid tumors (ATRT), rhabdomyosarcoma, Ewing sarcoma, MRT (malignant rhabdoid tumor), Wilms tumor, other undisclosed tumors defined by overexpression of PTGR1, brain metastasis including lung cancer, melanoma, triple-negative breast cancer and non-small cell lung cancer. The drug candidate is administered through intravenous and parenteral route. It is a hydroxyurea derivative of irofulven. The drug candidate is a non-hormone, non-chemotherapy, next-generation DNA damage repair (DDR) inhibitor. It is developed based on theranostics 5M approach and RADR artificial intelligence machine learning (ML) platform.

It was also under development for lung adenocarcinoma, renal cell cancer.

Lantern Pharma overview

Lantern Pharma is a clinical-stage biopharmaceutical company. It develops precision cancer drugs using machine learning techniques, genomic data and precision oncology trials. The company’s pipeline products include LP-100 and LP-184 are non-hormone, non-chemotherapy, DNA Damage Repair (DDR) inhibitors showing multiple cytotoxic effects on tumor cell biology including DNA adduct formation, RNA polymerase stalling and redox protein modification in prostate, ovarian, renal, lung and brain cancers and LP-300 is a first-in-class combination agent indicated for non-small cell lung cancer (NCSLC). Lantern Pharma utilizes Response Algorithm for Drug Positioning & Rescue (RADR) which is an integrated data analytics and machine learning-based platform for patient genetic profiling for robust drug response prediction. The company partners with hospitals, diagnostics, non-profit organizations and universities to accelerate the development of small molecule-based therapies in oncology. Lantern Pharma is headquartered in Dallas, Texas, the US.

For a complete picture of LP-184’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.